TARA Biosystems Partners with Scipher Medicine®

Scipher to use proprietary patient molecular data analyzed by its SpectraTM platform to identify novel drug targets. TARA Biosystems to progress selected targets in its BiowireTM II drug discovery platform for cardiac laminopathies. Partnership set to reduce target discovery and validation from years down …

READ MORE

VantAI and TARA Biosystems Partner to Discover New Medicines

NEW YORK, NY - (EurekAlert) - VantAI and TARA Biosystems today announced the launch of a biology-driven, AI-enabled collaboration for accelerated cardiac drug development. The partnership will leverage TARA’s state-of-the-art in vitro human …

READ MORE

TARA Biosystems Report Study Results Demonstrating In Vitro Cardiac Biology Model Mimics Human Drug Response

NEW YORK, NY - (EurekAlert) - TARA Biosystems today reported study results demonstrating the ability of TARA’s in vitro human cardiac models to reproduce drug responses similar to those observed in humans. Appearing …

READ MORE

TARA Biosystems Announces $10 Million Series A2 Financing to Expand its Cardiac Disease Drug Discovery and Development Capabilities

NEW YORK, NY - (BUSINESS WIRE) - TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 …

READ MORE

TARA Biosystems Presents Translational Disease Models at Keystone Heart Failure Symposium

Tuesday March 3, 2020 – Keystone, Colorado.  TARA Biosystems Inc. today reported data showcasing its Biowire™ II as a platform for heart failure drug discovery.  Speaking at this year's Keystone

READ MORE